All HSG Trials and Studies

All HSG Trials & Studies

Study nameDescriptionSponsorCourseHSG sitesParticipants
CARE-HDCo-Enzyme Q10 And Remacemide: Evaluation in HDNIH (NINDS)1997-200223347
COHORTCooperative Huntington's Disease Observational Research TrialHigh Q Foundation/CHDI2006-2011452200
CreatinePilot Study using Creatine in Patients with Huntington's DiseaseHDSA1999-2004350
CREST-ECreatine Safety, Tolerability, and Efficacy in Huntington's diseaseNIH (NCCAM), FDA (Orphan Products
Division)
2007-201345650
DIMOND AA Multi-Center, Phase 1-2a, Open-Label, Dosage-Escalation Study of
Dimebon in Subjects with Huntington's Disease
Medivation, Inc.2006-20081255-111
DIMOND BA Multi-Center, Phase II, Study of Dimebon in Subjects with
Huntington's Disease
Medivation, Inc2007-20101790
DOMINOA Multi-Center, Pilot Study of Minocycline in Huntington's DiseaseFDA (Orphan Drug Division)2005-200912125
HARTA Multi-Center, Study Comparing Three Doses Of ACR16 Versus Placebo for
the Symptomatic Treatment of Huntington Disease
NeuroSearch Sweden, AB2008-201235220
HORIZONA Multi-Center, Phase III Safety and Efficacy Study of Dimebon in Patients
with Mild-To-Moderate Huntington Disease
Medivation, Inc. in collaboration with
Pfizer, Inc.
2009-201250350
INTRO-HDInvestigation of Tolerability in a Trial of OPC 14-117 in HDOtsuka American Pharmaceuticals,
Inc.
1994-1996464
MINOMinocycline Dosing and Safety in Huntington's DiseaseFDA (Orphan Drug Division), HDSA,
HDF
2001-2005863
PHAROSProspective Huntington At Risk Observational StudyNIH (NHGRI, NINDS), High Q
Foundation/CHDI
1998-2013431001
PHEND-HDPhenylbutyrate Development for Huntington's DiseaseNIH (NINDS), HP Therapeutics
Foundation, Inc.
2005-2008660
Pre-2CAREPilot Safety and Tolerability Study of Coenzyme Q10 in Huntington's
Disease and in Normal Subjects
High Q Foundation/CHDI 22003-2004430
PREQUELA Multi-Center, Tolerability Study of Coenzyme Q10 (UbiquinonE) in PREmanifest
Huntington's Disease
NIH (NINDS)2009-20121090
QuBECoenzyme Q10 (Ubiquinone) Bioequivalence StudyHigh Q Foundation/CHDI2003-2005124
Reach2HDA Multi-Center, Phase II Safety and Tolerability Trial of PBT2 in Patients
with Early to Mid-stage HD
Prana Biotechnology Ltd.2012-201320100
RESPONDAn Examination of Responses to Potential Discrimination from Individuals at Risk for HD) NIH (NHGRI)2005-200817400
RID-HDRIluzole Dosing in Huntington's DiseaseFDA (Orphan Drug Division)1999-2003963
START-HDShort Term Assessment of Remacemide Tolerability in HDFisons Pharmaceuticals, Inc.1993-1994131
TETRA-HDA Study of Tetrabenazine in Patients with Huntington's ChoreaPrestwick Pharmaceuticals, Inc.2003-20081684
TREND-HDA Multi-Center, Trial of Ethyl-EPA (Miraxion) in Subjects with Mild to
Moderate Huntington's Disease
Amarin Neurosciences, Ltd.2004-200843316
UHDRSUnified Huntington's Disease Rating Scale (UHDRS)Huntington Study Group1994, 99-2000277000
LEGATO-HDA multinational, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of laquininmod as treatment in patients with Huntington’s DiseaseTeva2014-201613~400
Pride-HDA randomized, double blind Phase II research study of the effects of pridopidine in patients with Huntington's DiseaseTeva2013-201520~400
ARC-HDAn open label, long term safety study of SD-809 ER in patients with chorea associated with Huntington's diseaseAuspex2013-201534119
First-HDA Randomized, Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea associated with Huntington's DiseaseAuspex2013-20153490
SIGNALA randomized, double-blind, Phase 2 research trial for people who are at risk for Huntington Disease (HD) and have early signs of HD. The study will asses the safety, tolerability, and effectiveness of VX15 (a novel monoclonal antibody).Vaccinex2015 - 23
2CARECoenzyme Q10 (CoQ) in Huntington Disease.NIH2003-201450608
PREDICT-HDNeurobiological predictors of Huntington diseaseNID, High Q Foundation/CHDI2002-201524900
Horizon PlusAn open-label extension study of the HORIZON protocol evaluating the safety of dimebon (latrepirdine) in subjects with Huntington Disease.Medivation (with Pfizer)2010-201250350
Open-HARTA Multi-center, North American, Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease NeuroSearch Sweden2010 - 22~220
TETRA Long TermA Study of Tetrabenazine in Patients with Huntington’s ChoreaPrestwick2003-20061654
TETRA WithdrawalA Study of Tetrabenazine in Patients with Huntington’s ChoreaPrestwick2003-2008130
AWARESurvey examining barriers to participation in clinical trials
Huntington Study Group2010N/A618

For more information on HD trials, visit:

HDTrialFinder

Clinical Trials . GOV